𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐕𝐢𝐬𝐢𝐨𝐧 𝐁𝐞𝐡𝐢𝐧𝐝 𝐀𝐫𝐛𝐞𝐥𝐞: 𝐀𝐧 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐈𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐰𝐢𝐭𝐡 𝐎𝐮𝐫 𝐅𝐨𝐮𝐧𝐝𝐞𝐫 𝐚𝐧𝐝 𝐂𝐄𝐎, 𝐉𝐨𝐡𝐧 𝐋𝐔𝐊 We’re thrilled to share an insightful conversation between our founder and CEO, John LUK and PharmaBoardroom. In this interview, John dives into the journey and inspiration behind founding Arbele, our unwavering passion for daily innovation, and the challenges faced during clinical trials. He also discusses the exciting potential of our groundbreaking innovations to revolutionize cancer treatment. Don’t miss this opportunity to learn more about Arbele’s mission and vision. Click the link to read the full interview! https://lnkd.in/g68UF8nf #Biotech #Innovation #CancerResearch #Leadership #ClinicalTrials #Healthcare #Pharma
About us
Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.
- Website
-
https://arbelebio.com/
External link for Arbele
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Bellevue, Washington
- Type
- Privately Held
- Specialties
- Immune Oncology, Stem cells, Biopharmaceutics, Biomarkers, In-vitro diagnostics, and CAR therapy
Locations
-
Primary
Get directions
13555 SE 36th St
Bellevue, Washington 98006, US
-
Get directions
Hong Kong Science Park
Shatin, HK
-
Get directions
Sydney, NSW, AU
-
Get directions
36 Huanyu 3rd Road
Units 409/410 4th Floor Building B Guangzhou Bioscience Innovation Center
Guangzhou, Guangzhou 000000, CN
Employees at Arbele
Updates
-
🎉 We are at BIO! Find us at Booth 5607 (Hong Kong Pavilion) or DM us to arrange for a meeting! Look forward to meeting and discussing great science! #partnering #BIO2024
-
-
Arbele reposted this
📣 We are excited to provide updates on cabotamig (ARB202), our lead asset CDH17xCD3 bispecific T-cell engager. Independent DMC members recommends to continue the Ph1 clinical trial A001 after reviewing the data from 18 patients, which also includes patients being treated with multiple doses of cabotamig. This confirms the tolerability profile of cabotamig is consistent with published safety data of T-cell engagers in other indications. This allows us to better understand the safety profile of cabotamig while optimizing the dosing regime. https://lnkd.in/gjpDDg6P #oncology #tcellengager #innovation #safety #drugdevelopment
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers
prnewswire.com
-
📣 We are excited to provide updates on cabotamig (ARB202), our lead asset CDH17xCD3 bispecific T-cell engager. Independent DMC members recommends to continue the Ph1 clinical trial A001 after reviewing the data from 18 patients, which also includes patients being treated with multiple doses of cabotamig. This confirms the tolerability profile of cabotamig is consistent with published safety data of T-cell engagers in other indications. This allows us to better understand the safety profile of cabotamig while optimizing the dosing regime. https://lnkd.in/gjpDDg6P #oncology #tcellengager #innovation #safety #drugdevelopment
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers
prnewswire.com
-
We are heading to AACR! 🎉 Arbele will present data from 4 discovery/preclinical programs and 1 diagnostics program in poster presentations at the American Association of Cancer Research (AACR) meeting, which will be held in San Diego, US, from 5-10 Apr 2024. These represent the important studies in different therapeutic modalities in the GI cancers space, demonstrating our continuous innovation at Arbele. We are proud of our significant progress made over the last years and are excited to have the opportunity to share our data. We look forward to further push these programs into preclinical and clinical validations. 💡 Abstract: 3131/12 Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers https://lnkd.in/gQhDY6Kz 💡Abstract: 3212/29 Development of a Trop2/CD3 bispecific antibody with modulated Trop2 binding affinity as a novel immunotherapy for advanced gastrointestinal cancer treatment https://lnkd.in/gHJ6QNCu 💡Abstract: 3213/30 A novel CDH17/PD-1 bispecific antibody for treatment of advanced gastrointestinal cancers https://lnkd.in/gMaE6Hub 💡Abstract: 1326/9 Pre-clinical development of ARB011: A CDH17 targeting allogeneic nonviral RNA-based “Flash” CAR-NK therapy for gastrointestinal cancer https://lnkd.in/g3W5BZWt 💡Abstract: 1061/9 Diagnostic application of a novel blood CDH17 immunoassay in the detection of colorectal adenoma https://lnkd.in/gwJ398BR
-
-
🎉 Arbele wins the Gold Award at the 3rd Asia Exhibition of Innovations & Inventions Hong Kong last Friday! With over 110 inventions from Hong Kong, Mainland China, Russia, Korea and Thailand, we are honored to be selected by a 22-member Jury Panel presided by Mr David Taji, who has served as the President of the Jury of Inventions Geneva. Our lead asset, ARB202, is currently in Ph1 clinical trial in advanced gastrointestinal cancers. We are highly excited about receiving new patient data in the coming months! #innovation #competition #exhibition #ecosystem #biotech #oncology #clinicaltrial
【Celebrating our exciting news at 3rd AEII 】 🌟 Exciting news from the 3rd Asia Exhibition of Innovations and Inventions in Hong Kong! Taking place at HKCEC on 7-8 Dec 2023, CityU once again demonstrates its outstanding innovative prowess. Among the 24 awards won by 23 CityU teams, we are proud to have won the prestigious Special IFIA Award and two Gold with Congratulations of Jury Award out of more than 110 inventions. Other awards included 5 Gold, 14 Silver and 2 Bronze. Let's celebrate the incredible achievements of the award-winning teams: 1. CityU - Negative Reactance: A Game Changing Device for Power Applications (IFIA Award & Gold with Congratulations of Jury - Prof C K Michael Tse & research team) 2.CityU - ClusterAD: Method of Presenting Flight Data of an Aircraft and a Graphical User Interface for Use with the Same (Gold Medal with Congratulations of Jury - Prof Li Lishuai & research team) 3.CityU - Multi-Site Integrated Power Converters for DC Distribution Networks of Data Centers (Gold Medal - Prof Derrick C Q Jiang & research team) 4. Arbele Limited (Gold Medal) 5. i2COOL Limited (Gold Medal) 6. S3Tough Tech Co. Limited (Gold Medal) 7. Seth Biotech Limited (Gold Medal) Congratulations to all the faculty and HK Tech 300 startup teams for their dedication, hard work, and innovative spirit. CityU continues to push the boundaries of innovation, and we take pride in being part of this incredible institution. #AEII #HKTech300 #CityU #KTO #University #HKTDC #HKCEC #IEIG #cityukto #cityuers
-
-
-
-
-
+4
-
-
We strongly believe in being part of the ecosystem that encourages innovation. Our CEO spoke about our advancements in cancer immunotherapy over the weekend at the 2023 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship. It was really great to meet with like-minded personnel and share our journey.
Today's Emerging Oncology Companies Showcase at the 2023 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by AFCR, was a testament to innovation and resilience. AFCR’s BRACE Awardees, Dr. Ignacio (Nacho) Asial of DotBio and Dr. John Luk of Arbele, shared insights into the development of their groundbreaking technologies. DotBio’s rapid creation of multi-functional antibodies and Arbele’s advancements in gastrointestinal cancer immunotherapy are shaping the future of cancer treatment. Stay tuned for more highlights from the summit and be part of our shared mission to make strides in cancer research and treatment. #AFCR #CancerResearch #GlobalSummit #OncologyCompanies #BRACEAward
-
-
Join us virtually for the 2023 Global Summit for Cancer Research & Entrepreneurship! From the in-depth discussions at the New Frontiers for Cancer Research segment and Emerging Oncology Companies Showcase to the esteemed Szent-Györgyi Prize Award Ceremony honoring Dr. Isaac P. Witz, this summit promises a comprehensive look into the future of oncology. Be part of a global movement from wherever you are and dive deep into innovation, collaboration, and the collective drive to advance cancer research and patient care. Secure your digital pass today: bit.ly/3ETwWUF
-
Our CEO John Luk will be speaking at the 2023 Global Summit for Cancer Research & Entrepreneurship organized by National Foundation for Cancer Research (NFCR). Do register in the link below to be part of this event! #innovation #entrepreneur #cancerresearch #oncology
This 21 October, take part in the exclusive Emerging Oncology Companies Showcase at the 2023 Global Summit for Cancer Research & Entrepreneurship, featuring Dr. John Luk, CEO and Co-Founder of Arbele. As the 2020 BRACE Award Winner, Arbele is pioneering immunotherapy treatments for gastrointestinal cancers. Register today to be part of this transformative dialogue, where innovation, entrepreneurship, and global impact converge: bit.ly/3ETwWUF #AFCR #CancerResearch #GlobalSummit #OncologyCompanies #BRACEAwards #GastroIntestinalCancers
-